SCHEMBL21521286

SCHEMBL21521286

COC(=O)CN(Cc1cccnc1Cl)C(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.40
ATR Q13535 1/20 0.39
SSTR4 P31391 1/20 0.37
CASP3 P42574 1/20 0.35
SENP8 Q96LD8 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
SENP6 Q9GZR1 1/20 0.35
KDM4E B2RXH2 1/20 0.35
TDP1 Q9NUW8 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
NCOR2 Q9Y618 1/20 0.34
ALDH1A1 P00352 3/20 0.34
MAPT P10636 3/20 0.34
SMN1; SMN2 Q16637 3/20 0.33
MAPK8 P45983 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
HTT P42858 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29865792 0.80 POLB (0.44) POLBATRSSTR4CASP3SENP8
SCHEMBL21257735 0.79 REN (0.35) HDAC3HDAC1HDAC2NCOR2SMN1; SMN2
SCHEMBL20565289 0.78 HDAC3 (0.38) POLBKDM4ETDP1HDAC3HDAC1
SCHEMBL3406057 0.78 HDAC3 (0.39) KDM4ETDP1HDAC3HDAC1HDAC2
SCHEMBL21257783 0.76 ALDH1A1 (0.39) ALDH1A1MAPTSMN1; SMN2
SCHEMBL7299608 0.76 HDAC3 (0.45) HDAC3HDAC1HDAC2NCOR2ALDH1A1
SCHEMBL31224074 0.76 HDAC3 (0.35) SSTR4TDP1HDAC3HDAC1HDAC2
SCHEMBL21257568 0.75 ABL1 (0.40) KDM4EALDH1A1MAPTSMN1; SMN2NPSR1
SCHEMBL20565261 0.75 POLB (0.47) POLBATRCASP3SENP8SENP7
SCHEMBL23257193 0.75 HDAC3 (0.37) SSTR4TDP1HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS, INC. 2025-01-30 US disclosed
EP-4234551-A2 PYRIDAZINONES AS PARP7 INHIBITORS Ribon Therapeutics Inc. (US) 2023-08-30 EP disclosed
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2023-06-22 US disclosed
EP-3788040-B1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS INC (US) 2023-04-12 EP disclosed
US-11566020-B1 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2023-01-31 US disclosed
US-11014913-B2 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2021-05-25 US disclosed
EP-3788040-A1 PYRIDAZINONES AS PARP7 INHIBITORS Ribon Therapeutics Inc. (US) 2021-03-10 EP disclosed
CN-112424188-A Pyridazinones as PARP7 inhibitors 里邦医疗公司 2021-02-26 CN disclosed
US-20210024502-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2021-01-28 US disclosed
US-10870641-B2 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2020-12-22 US disclosed
US-20200123134-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2020-04-23 US disclosed
US-10550105-B2 Pyridazinones as PARP7 inhibitors Ribon Therapeutics Inc. (US) 2020-02-04 US disclosed
US-20190330194-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2019-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210024502-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 POLB 110/4885ATR 218/4885SSTR4 4518/4885
US-10550105-B2 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 POLB 110/4885ATR 218/4885SSTR4 4518/4885
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 POLB 110/4885ATR 218/4885SSTR4 4518/4885
US-20190330194-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 POLB 110/4885ATR 218/4885SSTR4 4518/4885
US-11014913-B2 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 POLB 110/4885ATR 218/4885SSTR4 4518/4885
US-11566020-B1 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 POLB 110/4885ATR 218/4885SSTR4 4518/4885
US-10870641-B2 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 POLB 110/4885ATR 218/4885SSTR4 4518/4885
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 POLB 110/4885ATR 218/4885SSTR4 4518/4885
US-20200123134-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 POLB 110/4885ATR 218/4885SSTR4 4518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.